胶质母细胞瘤研究性治疗的II期阳性临床试验无法随后预测III期阳性临床试验
该研究通过PubMed检索过去25年新诊断或复发胶质母细胞瘤的III期临床试验,纳入7项新诊断和4项复发III期试验,仅1项(9%)III期研究显示总生存改善并改变标准治疗,表明II期阳性结果难以预测III期成功,作者提出需提高II期试验可靠性并测试适应性设计、贝叶斯统计、生物标志物、容积成像和数学建模等策略。
要点
- 7项新诊断和4项复发胶质母细胞瘤III期试验纳入分析。
- 仅1项(9%)III期研究显示总生存改善并改变标准治疗。
- 作者认为需提高II期试验的可靠性以增加III期成功概率。
核心结论
- III期试验的高失败率表明迫切需要提高胶质母细胞瘤治疗II期试验的可靠性。
- 作者认为适应性试验设计、贝叶斯统计、生物标志物、容积成像和数学建模等策略值得测试。
- 作者认为提高对II期试验的期望至关重要,以使阳性发现增加III期试验成功的概率。
研究设计与样本
- 通过PubMed检索过去25年在新诊断或复发胶质母细胞瘤患者中进行的III期临床试验。
- 排除未研究试验性化疗或药物、因毒性提前终止、缺乏先前II期研究或先前II期研究为阴性的试验。
- 7项新诊断胶质母细胞瘤III期临床试验和4项复发胶质母细胞瘤III期临床试验符合纳入标准。
主要发现
- 仅1项(9%)III期研究记录了总生存改善并改变了标准治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is the most common primary malignant brain tumor in adults, but effective therapies are lacking. With the scarcity of positive phase III trials, which are increasing in cost, we examined the ability of positive phase II trials to predict statistically significant improvement in clinical outcomes of phase III trials. METHODS: A PubMed search was conducted to identify phase III clinical trials performed in the past 25 years for patients with newly diagnosed or recurrent glioblastoma. Trials were excluded if they did not examine an investigational chemotherapy or agent, if they were stopped early owing to toxicity, if they lacked prior phase II studies, or if a prior phase II study was negative. RESULTS: Seven phase III clinical trials in newly diagnosed glioblastoma and 4 phase III clinical trials in recurrent glioblastoma met the inclusion criteria. Only 1 (9%) phase III study documented an improvement in overall survival and changed the standard of care. CONCLUSION: The high failure rate of phase III trials demonstrates the urgent need to increase the reliability of phase II trials of treatments for glioblastoma. Strategies such as the use of adaptive trial designs, Bayesian statistics, biomarkers, volumetric imaging, and mathematical modeling warrant testing. Additionally, it is critical to increase our expectations of phase II trials so that positive findings increase the probability that a phase III trial will be successful.
引用
- Mandel JJ, Yust-Katz S, Patel AJ, et al. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol. 2018. PMID: 29016865. doi:10.1093/neuonc/nox144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。